{"eventGroups":[{"deathsNumAffected":13,"deathsNumAtRisk":31,"description":"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.\n\nNOTE: \\*After one year of treatment, dexamethasone is tapered for an additional 4 weeks.\n\nClarithromycin: Given Orally (PO)\n\nDexamethasone: Given PO\n\nLenalidomide: Given PO","id":"EG000","otherNumAffected":19,"otherNumAtRisk":31,"seriousNumAffected":11,"seriousNumAtRisk":31,"title":"Treatment (Clarithromycin, Dexamethasone, Lenalidomide)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grades 2 and 3 only occurred","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":31}],"term":"Peripheral Neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grades 2-4 reported, grade 2 ( n=3) , grade 3 (n=4), grade 4 (n=2).","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":31}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":31}],"term":"upper respiratory infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31}],"term":"sinus/acute otitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31}],"term":"cellulitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31}],"term":"vaginitis"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Upper Respiratory Syncytial Virus infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Varicella-zoster virus pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Cellulitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}],"term":"Pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Peripheral edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Pneumocystis Carinii Pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"H1N1 influenza / Streptococcus pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Ileus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Secondary cancer, Acute Myeloid Leukemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Upper respiratory syncytial viurs infection/Leukocytoclastic vasculitis"}],"timeFrame":"10.25 years"}